CliffBio
small molecule

TYBLUME

ETHINYL ESTRADIOL; LEVONORGESTREL

Loss of exclusivity—loss of exclusivity
CompanyExeltis USA, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameTYBLUME
Active ingredientETHINYL ESTRADIOL; LEVONORGESTREL
Strength0.02MG;0.1MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2020
Marketing statusRX

More from Exeltis USA, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TYBLUME patent cliff — loss of exclusivity — | CliffBio